Georgia Tech has posted its strongest year ever in research commercialization, breaking multiple records for invention disclosures, issued patents, and licensed technologies - clear indicators of the Institute's expanding role in delivering research-driven innovation to the marketplace.
"Invention is only the beginning. What sets Georgia Tech apart is our ability to move our ideas out of the lab and into the marketplace, where they can make a tangible impact on human life and contribute to our economy," said Ángel Cabrera, president of Georgia Tech. "This year's record results show that our researchers aren't just pushing the boundaries of knowledge - they're creating marketable solutions with the power to improve everyday lives."
For fiscal year 2025, Georgia Tech reported:
- More than 460 new invention disclosures - a 30% increase over the previous year and the highest ever recorded by the Institute.
- 70 invention disclosures for the Georgia Tech Research Institute, marking a 70% increase year over year.
- A 210% increase in technologies licensed, and 140% in total licenses executed, reflecting unprecedented industry interest, with 65 licenses in total.
- 124 U.S. patents were issued, representing a 20% increase compared to the prior year.
- In 2024, Georgia Tech is in the top 15 public universities for U.S. utility patents filed, according to the National Academy of Inventors.
This momentum strengthens Atlanta's position as one of the nation's fastest-growing innovation economies. Georgia Tech plays a leading role in advancing the region's ambition to become a top 5 tech hub by connecting world-class research with industry, supporting a thriving startup ecosystem, and fueling talent pipelines that serve emerging sectors like AI, cybersecurity, and clean energy.
Omer Inan, a Georgia Tech researcher and faculty member, has launched multiple companies with the support of the Institute's commercialization resources. Cardiosense is a medical AI company that leverages sensors to provide better management of cardiovascular disease. Having just achieved FDA 501(k) clearance, its latest device - CardioTag - is the first multimodal, wearable sensor that simultaneously captures three cardio signals to provide noninvasive solutions for heart health.
"The med tech research I conduct at Georgia Tech delivers new technologies to keep patients with heart failure out of the hospital and enables them to monitor their health status at home," said Inan. "Now, we are commercializing the technology our lab helped develop, so that this dream of improving the quality of care and life for millions of Americans with heart failure can one day become reality."
"As we look to solidify Georgia Tech's status as a national innovation hub, we are moving research into the marketplace so it can truly make a difference in people's lives," said Raghupathy "Siva" Sivakumar, vice president of Commercialization and chief commercialization officer at Georgia Tech. "We are at a pivotal moment to put Atlanta on the map as a leader in research commercialization and have an opportunity to capitalize on our $1.4 billion in research expenditures that drive meaningful inventions, IP, and industry partnerships."
To learn more about the licensing and commercialization process at Georgia Tech, visit licensing.research.gatech.edu.
